These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

597 related articles for article (PubMed ID: 35266651)

  • 21. The Gut Microbiome and Inflammatory Bowel Diseases.
    Shan Y; Lee M; Chang EB
    Annu Rev Med; 2022 Jan; 73():455-468. PubMed ID: 34555295
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The role of the gut microbiota in the treatment of inflammatory bowel diseases.
    Aggeletopoulou I; Konstantakis C; Assimakopoulos SF; Triantos C
    Microb Pathog; 2019 Dec; 137():103774. PubMed ID: 31586663
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Metabolic Influences of Gut Microbiota Dysbiosis on Inflammatory Bowel Disease.
    Sultan S; El-Mowafy M; Elgaml A; Ahmed TAE; Hassan H; Mottawea W
    Front Physiol; 2021; 12():715506. PubMed ID: 34646151
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Dynamic impact of virome on colitis and colorectal cancer: Immunity, inflammation, prevention and treatment.
    Wang Z; Guo K; Liu Y; Huang C; Wu M
    Semin Cancer Biol; 2022 Nov; 86(Pt 2):943-954. PubMed ID: 34656791
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Microbiome-phage interactions in inflammatory bowel disease.
    Federici S; Kviatcovsky D; Valdés-Mas R; Elinav E
    Clin Microbiol Infect; 2023 Jun; 29(6):682-688. PubMed ID: 36191844
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The Interplay between Immune System and Microbiota in Inflammatory Bowel Disease: A Narrative Review.
    Aldars-García L; Marin AC; Chaparro M; Gisbert JP
    Int J Mol Sci; 2021 Mar; 22(6):. PubMed ID: 33802883
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The gut microbes in inflammatory bowel disease: Future novel target option for pharmacotherapy.
    Yuan S; Wang KS; Meng H; Hou XT; Xue JC; Liu BH; Cheng WW; Li J; Zhang HM; Nan JX; Zhang QG
    Biomed Pharmacother; 2023 Sep; 165():114893. PubMed ID: 37352702
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Bile Acid-Gut Microbiota Axis in Inflammatory Bowel Disease: From Bench to Bedside.
    Yang M; Gu Y; Li L; Liu T; Song X; Sun Y; Cao X; Wang B; Jiang K; Cao H
    Nutrients; 2021 Sep; 13(9):. PubMed ID: 34579027
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Gut bacteriome, mycobiome and virome alterations in rheumatoid arthritis.
    Dagar S; Singh J; Saini A; Kumar Y; Chhabra S; Minz RW; Rani L
    Front Endocrinol (Lausanne); 2022; 13():1044673. PubMed ID: 36699026
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Fiber and Prebiotic Interventions in Pediatric Inflammatory Bowel Disease: What Role Does the Gut Microbiome Play?
    Healey GR; Celiberto LS; Lee SM; Jacobson K
    Nutrients; 2020 Oct; 12(10):. PubMed ID: 33092150
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effect of gut microbiota on colorectal cancer progression and treatment.
    Alasiri GA
    Saudi Med J; 2022 Dec; 43(12):1289-1299. PubMed ID: 36517053
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Dysbiosis of gut microbiota in inflammatory bowel disease: Current therapies and potential for microbiota-modulating therapeutic approaches.
    Alshehri D; Saadah O; Mosli M; Edris S; Alhindi R; Bahieldin A
    Bosn J Basic Med Sci; 2021 Jun; 21(3):270-283. PubMed ID: 33052081
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The Unexplored World of Human Virome, Mycobiome, and Archaeome in Aging.
    Barrera-Vázquez OS; Gomez-Verjan JC
    J Gerontol A Biol Sci Med Sci; 2020 Sep; 75(10):1834-1837. PubMed ID: 31802114
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Recent advances in gut Microbiota mediated therapeutic targets in inflammatory bowel diseases: Emerging modalities for future pharmacological implications.
    Shamoon M; Martin NM; O'Brien CL
    Pharmacol Res; 2019 Oct; 148():104344. PubMed ID: 31400403
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Gut microbiota in inflammatory bowel diseases: moving from basic science to clinical applications.
    Collij V; Klaassen MAY; Weersma RK; Vila AV
    Hum Genet; 2021 May; 140(5):703-708. PubMed ID: 32857194
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Current understanding of microbiota- and dietary-therapies for treating inflammatory bowel disease.
    Eom T; Kim YS; Choi CH; Sadowsky MJ; Unno T
    J Microbiol; 2018 Mar; 56(3):189-198. PubMed ID: 29492876
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The Neglected Gut Microbiome: Fungi, Protozoa, and Bacteriophages in Inflammatory Bowel Disease.
    Guzzo GL; Andrews JM; Weyrich LS
    Inflamm Bowel Dis; 2022 Jul; 28(7):1112-1122. PubMed ID: 35092426
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Therapeutic Advances in Gut Microbiome Modulation in Patients with Inflammatory Bowel Disease from Pediatrics to Adulthood.
    Eindor-Abarbanel A; Healey GR; Jacobson K
    Int J Mol Sci; 2021 Nov; 22(22):. PubMed ID: 34830388
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Examining the gut bacteriome, virome, and mycobiome in glucose metabolism disorders: Are we on the right track?
    Stefanaki C; Peppa M; Mastorakos G; Chrousos GP
    Metabolism; 2017 Aug; 73():52-66. PubMed ID: 28732571
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Synergic interactions between polyphenols and gut microbiota in mitigating inflammatory bowel diseases.
    Li H; Christman LM; Li R; Gu L
    Food Funct; 2020 Jun; 11(6):4878-4891. PubMed ID: 32490857
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 30.